BIIB: Biogen Inc. Common Stock Company Profile & Statistics

Biogen Inc. Common Stock Profile

About

Biogen Inc. is one of the world's leading biotechnology companies which focuses on developing innovative therapies for treating serious neurological and neurodegenerative diseases, including its core growth areas of multiple sclerosis (MS) and neuroimmunology, Alzheimer's disease (AD) and dementia, movement disorders including Parkinson's disease, neuromuscular disorders, including spinal muscular atrophy (SMA) and amyotrophic lateral sclerosis (ALS) and ophthalmology. Key multiple sclerosis/MS drugs in its portfolio are Tecfidera, Vumerity, Avonex, Plegridy, Fampyra and Tysabri. Other approved/marketed products include Fumaderm (severe psoriasis), Spinraza (spinal muscular atrophy (SMA)) and Aduhelm (Alzheimer's disease).

Info & Links

CEO

Christopher A. Viehbacher

Headquarters

225 BINNEY STREET
CAMBRIDGE, MA 02142, UNITED STATES

Auditor

PricewaterhouseCoopers LLP

Share holders

392

Employees

7,605

Biogen Inc. Common Stock Statistics

Valuation Measures

Market Capitalization²

21.40B

Enterprise Value

24.93B

Enterprise Value/EBITDA(ttm)

8.08

Price to Earnings Ratio(ttm)

9.05

Price to Sales(ttm)

2.12

Price to Book(mrq)

1.20

Price to Cash(ytd)

6.27

Profitability

Gross Margin(ttm)

75.39%

Operating Margin(ttm)

23.44%

Profit Margin(ttm)

15.13%

Return on Equity(ttm)

13.85%

Return on Invested Capital(ttm)

6.88%

Return on Assets(ttm)

8.32%

Income Statement

Revenue(ttm)

10.00B

Revenue Per Share(ttm)

68.19

Gross Profit(ttm)

7.54B

EBITDA(ttm)³

3.09B

Net Income Available to Common(ttm)

1.53B

Diluted EPS(ttm)

10.46

Share Statistics

Beta (5Y Monthly)

0.11

52-Week Change

-25.93%

S&P 500 52-Week Change

16.89%

S&P 500 Member

Yes

Stock Optionable

Yes

Total Shares Outstanding¹

146.61M

Dividend Yield

0.00%

Float⁴

146.35M

% Held by Insiders

0.18%

% Held by Institutions

87.93%

Balance Sheet

Total Cash(mrq)

2.76B

Total Cash Per Share(mrq)

18.82

Total Debt(mrq)

6.28B

Total Debt/Equity(mrq)

35.63%

Current Ratio(mrq)

2.50%

Quick Ratio(mrq)

1.79%

Book Value Per Share(mrq)

120.29

Cash Flow

Operating Cash Flow Per Share(ytd)

2.86

Free Cash Flow(ytd)

356.50M

Table Key

mrq = Most Recent Quarter

ttm = Trailing Twelve Months

ytd = Year To Date

Footnotes

Data provided by Zacks Investment Research or calculated by FXEmpire. All numbers are rounded to the closest decimal.

1 Total Shares outstanding is taken from the most recently filed quarterly or annual report.
2 Market Cap is calculated using total shares outstanding and the most recent share price.
3 EBITDA is calculated using methodology that may differ from that used by a company in its reporting.
4 The float is a measure of the number of shares available for trading by the public. It's calculated by taking the number of issued and outstanding shares minus any restricted stock, which might not be publicly traded.

BIIB

Biogen Inc. Common Stock